Westfield Capital Management Co. LP Boosts Stock Holdings in Icon Plc $ICLR

Westfield Capital Management Co. LP lifted its position in Icon Plc (NASDAQ:ICLR) by 14.6% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 396,354 shares of the medical research company’s stock after acquiring an additional 50,526 shares during the quarter. Westfield Capital Management Co. LP’s holdings in Icon were worth $69,362,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ICLR. Private Trust Co. NA lifted its position in shares of Icon by 200.0% during the third quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 94 shares in the last quarter. Wilmington Savings Fund Society FSB increased its stake in Icon by 153.4% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 332 shares of the medical research company’s stock valued at $58,000 after buying an additional 201 shares during the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new stake in Icon in the 3rd quarter valued at about $63,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new position in shares of Icon during the 2nd quarter worth approximately $61,000. Finally, Geneos Wealth Management Inc. boosted its stake in shares of Icon by 11.5% in the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after buying an additional 56 shares during the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ICLR shares. Mizuho set a $216.00 target price on Icon in a report on Friday, January 9th. Zacks Research raised Icon from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 25th. Jefferies Financial Group set a $135.00 target price on Icon and gave the company a “buy” rating in a research report on Monday. Barclays lifted their target price on Icon from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research note on Monday, December 15th. Finally, BMO Capital Markets reissued a “market perform” rating and issued a $100.00 price target on shares of Icon in a report on Thursday, February 12th. Six investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $157.47.

Icon Price Performance

Shares of NASDAQ:ICLR opened at $101.00 on Thursday. The firm has a market capitalization of $8.16 billion, a PE ratio of 13.67, a P/E/G ratio of 2.60 and a beta of 1.27. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The company has a 50-day moving average price of $162.21 and a two-hundred day moving average price of $171.14. Icon Plc has a twelve month low of $66.57 and a twelve month high of $211.00.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.